Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study
Phase of Trial: Phase I
Latest Information Update: 29 May 2017
At a glance
- Drugs Chiauranib (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 23 May 2017 Planned End Date changed from 1 Mar 2019 to 1 May 2019.
- 23 May 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.
- 23 May 2017 Status changed from not yet recruiting to recruiting.